cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Intra Cellular Therapies Inc
11 own
15 watching
Current Price
$47.92
$0.93
(1.98%)
logo-itci
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,538.1M
52-Week High
52-Week High
66
52-Week Low
52-Week Low
42.42
Average Volume
Average Volume
0.73M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization4,538.1M
icon52-Week High66
icon52-Week Low42.42
iconAverage Volume0.73M
iconDividend Yield--
iconP/E Ratio--
What does the Intra Cellular Therapies Inc do?
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Read More
How much money does Intra Cellular Therapies Inc make?
News & Events about Intra Cellular Therapies Inc.
Globe Newswire
29days ago
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and ...
Globe Newswire
1month ago
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced four data presentations at the American College of ...
Globe Newswire
2 months ago
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor ...
Frequently Asked Questions
Frequently Asked Questions
What is Intra Cellular Therapies Inc share price today?
plus_minus_icon
Can Indians buy Intra Cellular Therapies Inc shares?
plus_minus_icon
How can I buy Intra Cellular Therapies Inc shares from India?
plus_minus_icon
Can Fractional shares of Intra Cellular Therapies Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Intra Cellular Therapies Inc stocks?
plus_minus_icon
What is today’s traded volume of Intra Cellular Therapies Inc?
plus_minus_icon
What is today’s market capitalisation of Intra Cellular Therapies Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Intra Cellular Therapies Inc?
plus_minus_icon
What percentage is Intra Cellular Therapies Inc down from its 52-Week High?
plus_minus_icon
What percentage is Intra Cellular Therapies Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$47.92
$0.93
(1.98%)
logo-itci
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00